Corvus Pharmaceuticals, Inc. (CRVS) Q4 2018 Earnings Results

Corvus Pharmaceuticals Misses on EPS, Stock Down 3.46%

Corvus Pharmaceuticals reported a loss of $0.36 per share, but there was no revenue reported. The stock reacted negatively, declining by 3.46%. The absence of guidance and key commentary may have contributed to investor uncertainty.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.36	N/A	—
Revenue	—	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Corvus Pharmaceuticals Misses on EPS, Stock Down 3.46%

Key numbers

Management commentary

Corvus Pharmaceuticals, Inc.

More earnings this week

Corvus Pharmaceuticals Misses on EPS, Stock Down 3.46%

Key numbers

Management commentary